Une des principales orientations de notre unité est l'utilisation des techniques de haute technologie telles que des puces à ADN, le Multiplex RT-PCR, le CGH, etc., pour tenter de caractériser les gènes ''clefs'' impliqués dans la carcinogenèse tumorale mais également les gènes impliqués dans la réponse ou l'absence de réponse aux traitements anticancéreux. Les résultats de ce recherche devraient permettre la définition de nouvelles sous-classes du cancer non reconnues par les facteurs clinico-pathologiques, et l'identification de nouveaux marqueurs pronostiques ou prédictifs d'une réponse au traitement anticancéreux. [The laboratory uses several molecular approaches to gain a better understanding of breast tumorigenesis, metastasis and the mechanisms involved in breast cancer drug resistance. It is acting in liaison between the fundamental research and clinical research (closely linked with the Breast International Group (BIG) and the TransBIG (translational research program of the BIG ' founded by Pr M Piccart) to insure faster application of these findings to the clinic. Research themes: - Identification of prognostic and predictive markers in breast cancer using high throughput technologies such gene expression arrays, CGH, microRNAs, deep sequencing etc. - Evaluation of the role of the tumor microenvironment (including immune components) in breast tumor invasion/dissemination - Molecular characterization of the minimal residual disease (circulating (CTCs) and disseminated (DTCs) breast tumor cells - Study of the role of the host in tumor invasion/dissemination and in the development of distant metastases (colonization) - Study of epigenetic changes associated with breast tumorigenesis and response to different therapeutics - Studies of functional readouts of key molecular pathways involved in breast tumorigenesis and response to different treatments including targeted agents (trastuzumab, AKT, mTOR, PI3K inhibitors etc)]